Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Alan Diehl

Showing results (1-10 of 177) with videos related to

Pageof 18
Sort By:
Cancer Biology & Therapy|January 31, 2004
The cyclin D3 knockout: a pound of redundancy with a dash of tissue specificityJ Alan Diehl
Cell Cycle (Georgetown, Tex.)|October 8, 2016
Cyclin D3: To translate or not to translateJ Alan Diehl
Cancer Biology & Therapy|November 15, 2002
Cycling to cancer with cyclin D1J Alan Diehl
Genes & Cancer|November 30, 2010
Ubiquitin-dependent proteolysis in G1/S phase control and its relationship with tumor susceptibilityJ Alan Diehl, Bhaskar Ponugoti
Journal of Molecular Medicine (Berlin, Germany)|October 4, 2016
Cyclin D1, cancer progression, and opportunities in cancer treatmentShuo Qie, J Alan Diehl
Journal of Cellular Physiology|February 12, 2016
PERK Integrates Oncogenic Signaling and Cell Survival During Cancer DevelopmentYiwen Bu, J Alan Diehl
Pigment Cell & Melanoma Research|June 16, 2016
Stressing out melanoma with an anti-GRP78 compoundYiwen Bu, J Alan Diehl
Oncoscience|October 2, 2015
PRMT5-dependent p53 escape in tumorigenesisYan Li, J Alan Diehl
Molecular & Cellular Oncology|June 19, 2019
Glutamine addiction: an Achilles heel in esophageal cancers with dysregulation of CDK4/6Shuo Qie, J Alan Diehl
Seminars in Cancer Biology|February 2, 2020
Cyclin D degradation by E3 ligases in cancer progression and treatmentShuo Qie, J Alan Diehl
Pageof 18

Showing results (1-10 of 177) with videos related to

Sort By:
Pageof 18
Cancer Biology & Therapy|January 31, 2004
The cyclin D3 knockout: a pound of redundancy with a dash of tissue specificityJ Alan Diehl
Cell Cycle (Georgetown, Tex.)|October 8, 2016
Cyclin D3: To translate or not to translateJ Alan Diehl
Cancer Biology & Therapy|November 15, 2002
Cycling to cancer with cyclin D1J Alan Diehl
Genes & Cancer|November 30, 2010
Ubiquitin-dependent proteolysis in G1/S phase control and its relationship with tumor susceptibilityJ Alan Diehl, Bhaskar Ponugoti
Journal of Molecular Medicine (Berlin, Germany)|October 4, 2016
Cyclin D1, cancer progression, and opportunities in cancer treatmentShuo Qie, J Alan Diehl
Journal of Cellular Physiology|February 12, 2016
PERK Integrates Oncogenic Signaling and Cell Survival During Cancer DevelopmentYiwen Bu, J Alan Diehl
Pigment Cell & Melanoma Research|June 16, 2016
Stressing out melanoma with an anti-GRP78 compoundYiwen Bu, J Alan Diehl
Oncoscience|October 2, 2015
PRMT5-dependent p53 escape in tumorigenesisYan Li, J Alan Diehl
Molecular & Cellular Oncology|June 19, 2019
Glutamine addiction: an Achilles heel in esophageal cancers with dysregulation of CDK4/6Shuo Qie, J Alan Diehl
Seminars in Cancer Biology|February 2, 2020
Cyclin D degradation by E3 ligases in cancer progression and treatmentShuo Qie, J Alan Diehl
Pageof 18